NasdaqGS:TYRABiotechs
Assessing Tyra Biosciences (TYRA) Valuation After William Blair Coverage And Dabogratinib Progress
Why Tyra Biosciences Is Back on Investors’ Radar
Tyra Biosciences (TYRA) has drawn fresh attention after William Blair initiated coverage highlighting its drug candidate dabogratinib, along with recent pipeline progress, the start of a Phase 2 trial, and new executive appointments that together helped spotlight the stock.
See our latest analysis for Tyra Biosciences.
Tyra’s share price has pulled back slightly in the last week but still sits at US$29.19 after a strong 90 day share price...